Summary unavailable.

Questions

Question 1

What is the primary therapeutic goal for the general use of Anti-Alzheimer's agents?

View answer and explanation
Question 2

What is the general mechanism of action for all Anti-Alzheimer's agents described in the text?

View answer and explanation
Question 3

What is the stated effect of current Anti-Alzheimer's agents on the progression of Alzheimer's dementia?

View answer and explanation
Question 4

What is the primary contraindication listed for the use of Anti-Alzheimer's agents?

View answer and explanation
Question 5

Why should Anti-Alzheimer's agents be used cautiously in patients with a history of 'sick sinus syndrome'?

View answer and explanation
Question 6

Concurrent use of Anti-Alzheimer's agents with which other class of drugs can increase the risk of GI bleeding?

View answer and explanation
Question 7

What is a potential cholinergic effect of Anti-Alzheimer's agents that would require cautious use in patients with a history of asthma?

View answer and explanation
Question 8

How do Anti-Alzheimer's agents interact with anticholinergic drugs?

View answer and explanation
Question 9

What is the expected interaction when Anti-Alzheimer's agents are administered with succinylcholine-type muscle relaxants during anesthesia?

View answer and explanation
Question 10

What is the primary nursing assessment that should be conducted throughout therapy with Anti-Alzheimer's agents?

View answer and explanation
Question 11

Which specific adverse GI effects should a nurse monitor for in a patient taking an Anti-Alzheimer's agent?

View answer and explanation
Question 12

Which potential nursing diagnosis is directly related to the intended use or 'Indications' of Anti-Alzheimer's agents?

View answer and explanation
Question 13

What is the key patient and caregiver instruction regarding the administration of Anti-Alzheimer's medication?

View answer and explanation
Question 14

What should a patient or caregiver be advised to do if nausea, vomiting, anorexia, or weight loss occurs while taking an Anti-Alzheimer's agent?

View answer and explanation
Question 15

What is the desired evaluation outcome for a patient with Alzheimer's disease taking an Anti-Alzheimer's agent?

View answer and explanation
Question 16

The cholinergic effects of Anti-Alzheimer's agents may lead to an increased risk of GI bleeding due to what mechanism?

View answer and explanation
Question 17

Which patient population requires cautious use of Anti-Alzheimer's agents due to a potential risk of urinary tract obstruction?

View answer and explanation
Question 18

What is the impact of Anti-Alzheimer's agents on a patient's quality of life, according to the text?

View answer and explanation
Question 19

The nursing diagnosis 'Imbalanced nutrition: less than body requirements' is related to which aspect of Anti-Alzheimer's agent therapy?

View answer and explanation
Question 20

Which nursing diagnosis for a patient on an Anti-Alzheimer's agent is related to patient and family teaching needs?

View answer and explanation
Question 21

What is the effect of Anti-Alzheimer's agents on the neurotransmitter acetylcholine?

View answer and explanation
Question 22

Which of the following is NOT listed as a potential cholinergic effect under the 'Precautions' for Anti-Alzheimer's agents?

View answer and explanation
Question 23

The 'General Action and Information' section indicates that Anti-Alzheimer's agents achieve their effect by inhibiting which enzyme?

View answer and explanation
Question 24

In addition to a history of 'sick sinus syndrome', cautious use of Anti-Alzheimer's agents is advised for patients with what other cardiac issue?

View answer and explanation
Question 25

What type of interaction occurs when Anti-Alzheimer's agents are taken with other drugs that also possess cholinergic properties?

View answer and explanation
Question 26

Which component of cognitive function should be assessed as part of the nursing implications for Anti-Alzheimer's agents?

View answer and explanation
Question 27

What is the therapeutic classification of Anti-Alzheimer's agents based on their general use?

View answer and explanation
Question 28

The potential for adverse GI effects from Anti-Alzheimer's agents is due to their what?

View answer and explanation
Question 29

What is the fundamental reason that current Anti-Alzheimer's agents only offer temporary improvement?

View answer and explanation
Question 30

Which assessment finding is a key part of the 'Evaluation/Desired Outcomes' for Anti-Alzheimer's agent therapy?

View answer and explanation
Question 31

According to the 'Pharmacologic Profile', what is the ultimate aim of temporarily improving cognitive function in patients with Alzheimer's dementia?

View answer and explanation
Question 32

What is the relationship between the cholinergic effects of Anti-Alzheimer's agents and adverse GI effects like nausea and vomiting?

View answer and explanation
Question 33

When assessing a patient on an Anti-Alzheimer's agent, which finding should prompt the nurse to notify a health care professional?

View answer and explanation
Question 34

What is the only absolute contraindication mentioned for the Anti-Alzheimer's agent drug class?

View answer and explanation
Question 35

The use of Anti-Alzheimer's agents should be cautious in patients with certain conditions because the drugs' cholinergic effects can cause what?

View answer and explanation
Question 36

Which of these is a listed potential nursing diagnosis for a patient on an Anti-Alzheimer's agent?

View answer and explanation
Question 37

What is the primary content of patient and caregiver teaching under the 'Implementation' section?

View answer and explanation
Question 38

Based on the text, what is the most accurate description of the therapeutic benefit of Anti-Alzheimer's agents?

View answer and explanation
Question 39

Which nursing action is indicated if a patient on an Anti-Alzheimer's agent who also takes NSAIDs develops signs of GI bleeding?

View answer and explanation
Question 40

The potential nursing diagnosis 'Disturbed thought process' is explicitly linked to what aspect of the drug profile?

View answer and explanation
Question 41

What is the primary reason for assessing a patient's ability to perform simple tasks when evaluating the effectiveness of Anti-Alzheimer's agents?

View answer and explanation
Question 42

How is the action of Anti-Alzheimer's agents on cholinesterase described?

View answer and explanation
Question 43

Which adverse effect listed under 'Precautions' is a specific concern for patients with pre-existing seizure disorders?

View answer and explanation
Question 44

The teaching plan for a patient starting an Anti-Alzheimer's agent should include telling the patient and caregiver to report what?

View answer and explanation
Question 45

What does the text indicate about the ability of Anti-Alzheimer's agents to alter the course of the disease?

View answer and explanation
Question 46

The interaction between Anti-Alzheimer's agents and anticholinergics is best described as what?

View answer and explanation
Question 47

In the context of nursing implications, which assessment is critical before administering an Anti-Alzheimer's agent to a patient with a history of cardiac issues?

View answer and explanation
Question 48

What is the primary evaluation criterion for the success of Anti-Alzheimer's agent therapy?

View answer and explanation
Question 49

A patient taking an Anti-Alzheimer's agent is scheduled for surgery. What potential interaction should the healthcare team be aware of?

View answer and explanation
Question 50

Which of the following is an example of a desired outcome for a patient with Alzheimer's disease on an appropriate therapeutic agent, as described in the text?

View answer and explanation

Other chapters

HOW TO USE DAVIS'S DRUG GUIDE FOR NURSESEVIDENCE-BASED PRACTICE AND PHARMACOTHERAPEUTICS: Implications for NursesPHARMACOGENOMICSMEDICATION ERRORS: Improving Practices and Patient SafetyDETECTING AND MANAGING ADVERSE DRUG REACTIONSOVERVIEW OF RISK EVALUATION AND MITIGATION SYSTEMS (REMS)SPECIAL DOSING CONSIDERATIONSTHE CYTOCHROME P450 SYSTEMEDUCATING PATIENTS ABOUT SAFE MEDICATION USEAntianemicsAntianginalsAntianxiety agentsAntiarrhythmicsAntiasthmaticsAnticholinergicsAnticoagulantsAnticonvulsantsAntidepressantsAntidiabeticsAntidiarrhealsAntiemeticsAntifungalsAntihistaminesAntihypertensivesAnti-infectivesAntineoplasticsAntiparkinson agentsAntiplatelet agentsAntipsychoticsAntipyreticsAntirheumaticsAntiulcer agentsAntiviralsBeta blockersBone resorption inhibitorsBronchodilatorsCalcium channel blockersCentral nervous system stimulantsCorticosteroidsDiureticsHormonesImmunosuppressantsLaxativesLipid lowering agentsMinerals/electrolytes/pH modifiersNonopioid analgesicsNonsteroidal anti-inflammatory agentsOpioid analgesicsSedative/hypnoticsSkeletal muscle relaxantsThrombolyticsVaccines/immunizing agentsVitaminsDRUGS APPROVED IN CANADANATURAL/HERBAL PRODUCTSMEDICATION SAFETY TOOLSAppendix A. Recent Drug ApprovalsAppendix E. Administering Medications to ChildrenAppendix G. Pediatric Dosage CalculationsAppendix I. Controlled Substance SchedulesAppendix L. Insulins and Insulin TherapyAppendix M. Canadian and U.S. Pharmaceutical PracticesAppendix N. Routine Pediatric and Adult Immunizations